Pfizer’s study shows that children aged 12 to 15 years are three times more likely than those who have been fully vaccinated to get Covid.
Only 30 (2.7%) of approximately 1,100 children tested positive in the US for the virus during the last four months.
The virus did not infect any of the children, and none were admitted to hospital or even died. They were only symptomatic or suffered from a mild condition.
None of the 1,100 children who received two doses of vaccine were positive.
Given the small number of cases in children, and the low chance of serious symptoms, it will be a heated debate as to whether or not they were bitten.
Still, concerns remain about myocarditis, a rare form of inflammation of the heart. It was found in approximately one-in-two children between 12 and 15 years old after receiving two doses Pfizer’s jab.
These new results were compiled in the period September to September. Pfizer boasted they had shown that its vaccine against Covid was 100 percent effective in children.
The US has already begun to give two doses to children aged 12-15 years old, and this is happening since September. However, the UK currently only offers one dose.
Because myocarditis seems to be more prevalent after 2 doses of vaccine, UK vaccination advisors are still waiting on more safety data.
Pfizer monitored 2,228 children, half of whom were given two injections of its vaccine — a 30 microgram dose, the same dose given to adults — three weeks apart, while the other group received a placebo jab. Pfizer claimed that its vaccine is 100 percent effective, as no child who received the jab was positive for it between 7 and 4 months later. 30 children were also positive for the vaccine, while those who had not received it tested negative.
The vaccine maker announced that two doses of Pfizer’s Covid jab are 100 percent effective in preventing infection among 12-15-year-olds. Because myocarditis (a rare form of heart inflammation) was more common in those who received the second dose, only one dose is available to them. Pictured is Quinn Foakes (15 years old) receiving the Covid-19 shot at Belfairs Academy, Leigh-on-Sea (Essex).
Fears over a very rare heart condition side effect — called myocarditis — led No10’s vaccine advisers, the Joint Committee on Vaccination and Immunisation (JCVI), to opt against routinely jabbing healthy 12 to 15-year-olds, who face a tiny risk of getting seriously ill from the virus. The risk that healthy children would be admitted to ICU by Covid was 2 in 1 million. This number could rise to 100 for those suffering from underlying diseases. For every dose of Covid, three to seventeen cases would occur for myocarditis. There would also be 12 to 35 cases in the next dose.
Vaccinating children remains a contentious issue among some parents and by November 14 just 38.4 per cent of 12 to 15-year-olds in England were vaccinated.
Pfizer monitored 2,228 children, half of whom were given two injections of its vaccine — a 30 microgram dose, the same dose given to adults — three weeks apart, while the other group received a placebo jab.
According to the company, its vaccine is 100% effective because it has no adverse effects on people who have had their jab for seven days or more.
The jab was effective for all children regardless of gender, race or health condition.
Tests have been positive for 30 children who weren’t given the jab.
The 2.7% Covid-related risk among trial participants could not hold true in real world data. This is because individual behavior and case level will determine the degree of risk.
It would be 72,000 cases if all 2.6million English 12-15 year-olds aren’t vaccinated.
Albert Bourla (Pfizer chairman and chief executive officers) said that the latest findings provide ‘further assurance’ about its vaccine. Safety and effectiveness.
Pfizer last night said that side effects from vaccines were the same as those in older age groups. They were also similar in severity to the ones seen in children who had received their first dose.
UK Government data indicates that nine of every million UK-born under-18s will contract myocarditis following a single Pfizer Covid Jab. That’s the same number as one for 110,000.
They will save around 150 children from Covid hospitalizations for each million vaccines they give.
Due to data from Israel and the USA, Joint Committee on Vaccination and Immunisation held back on recommending additional vaccines for children.
But real-world UK data in slightly older adults — who also saw above normal rates of myocarditis in other countries — was not higher after the second jab.
The reason is that there is a 12 week gap between the doses in the UK, but it takes between three to four weeks for the US.
The JCVI thinks that the shorter gap could be the ideal time to get a jab for natural infection among young people.
This led to a revision to the guidance that was made last week. The gap between children who have had positive tests and those who get their vaccines increased from 4 to 12 to 12.
Evidence also shows that myocarditis rates in Britain vary between 16-year-olds (and 17-year olds) and those aged 18-29 years, following the second jab.
Two jabs were recommended by the JCVI last week for healthier older teens.
It is still considering the evidence regarding younger children.
It’s not clear why there is a longer time period between vaccines and natural infections that reduces myocarditis risks.
This gap might give the immune system time to calm down from the reaction to the first dose or infection.
The body makes cells that fight Covid infections during immunization or Covid infected. The disease-fighting cells can cause muscle inflammation if they get into the heart.
Critics call it healthy Children aged between 12 and 15 years old are more likely to catch Covid and get protection naturally than being jabbed. According to the JCVI, one in 500,000 people are at risk of getting admitted to ICU.
Some studies suggest that myocarditis can occur even after Covid infection, complicating the situation further.
Bourla explained that these data give us more confidence about the safety and effectiveness of our vaccine in adolescents as the global health community works hard to boost the vaccination rate.
“This is particularly important because we are seeing rates of Covid rising in certain age groups in some areas, and vaccine uptake slowing.”
Ugur Sahin (CEO and Co-Founder of BioNTech) stated: “These are the only longer-term data that have been publicly disclosed and demonstrate the safety and effectiveness of the Covid vaccine for individuals aged 12-15 years.
“The increasing body of data that we have collected from clinical trials as well as real-world surveillance strengthens the evidence to support the positive safety profile and efficacy of the Covid vaccine in both adolescent, and adult populations.”
It stated that it would make the data available to medicine regulators all over the world.